New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Improved midterm outcomes after endovascular repair of nontraumatic descending thoracic aortic rupture compared with open surgery.
Improved midterm outcomes after endovascular repair of nontraumatic descending thoracic aortic rupture compared with open surgery. The Journal of thoracic and cardiovascular surgery Ogawa, Y., Watkins, A. C., Lingala, B., Nathan, I., Chiu, P., Iwakoshi, S., He, H., Lee, J. T., Fischbein, M., Woo, Y. J., Dake, M. D. 2019Abstract
BACKGROUND: Thoracic endovascular aortic repair (TEVAR) has become first-line treatment for descending thoracic aortic rupture (DTAR), but its midterm and long-term outcomes remain undescribed. This study evaluated whether TEVAR would improve midterm outcomes of nontraumatic DTAR relative to open surgical repair (OSR).METHODS: Between December 1999 and October 2018, 118 patients with DTAR were treated with either OSR (n=39) or TEVAR (n=79) at a single center. Primary end points were 30-day and long-term all-cause mortalities. Secondary end points included stroke, permanent spinal cord ischemia (SCI), prolonged ventilation support or tracheostomy, permanent hemodialysis, and aortic reintervention.RESULTS: Thirty-day mortality was significantly lower with TEVAR (OSR, 38.5%; TEVAR, 16.5%; P=.01). Stroke (15.6% vs 3.8%; P=.03), permanent SCI (15.6% vs 2.5%; P=.02), prolonged ventilation (30.8% vs 8.9%; P=.002), and tracheostomy (12.8% vs 2.5%; P=.04) were significantly lower after TEVAR than OSR. Need for hemodialysis trended higher after OSR (12.8% vs 5.1%; P=.2). Mean follow ups were 1048±1591days for OSR group and 828±1258days for TEVAR. All-cause mortality at last follow-up was significantly lower after TEVAR than OSR (35.4% vs 66.7%; P=.001). Aortic reintervention was required more frequently within 30days after TEVAR (15.2% vs 2.6%; P=.06). By multivariate analysis, TAAA was an independent predictor for mortality.CONCLUSIONS: TEVAR improves both early and midterm outcomes of DTAR relative to OSR. TAAA was a predictor of mortality. Endovascular approach to DTAR may provide the greatest chance at survival.
View details for DOI 10.1016/j.jtcvs.2019.10.156
View details for PubMedID 31926735